Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…

Stock Roche Holding AG RO.SW

Roche Holding AG — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 28.49%

Price change 2019 → 2020: 0.78%

Price change 2020 → 2021: 31.87%

Price change 2021 → 2022: -12.33%

Price change 2022 → 2023: -27.06%

Price change 2023 → 2024: 3.52%

Price change 2024 → 2025: 23.87%

Price change 2025 → 2026: 6.98%

Price change 2026 (year to date): 7.62%

Financial growth

Revenue CAGR (8 years): 0.48%

Earnings CAGR (8 years): 2.96%

Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.

Debt

Debt-to-equity ratio: 0.98

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 23.04

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 6.17% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Roche Holding AG26.50.98+1.7 %🔒
AstraZeneca PLC20.20.61+3.9 %–
Amgen Inc.20.86.31+6.1 %–
AbbVie Inc.28.9–+9.5 %–
Pfizer Inc.10.00.78−0.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

Key reported figures

Revenue, net income and net margin reported by Roche Holding AG over the latest fiscal years.

Revenue
75.0 bn USD
fiscal year 2025
Net income
15.7 bn USD
fiscal year 2025
Net margin
20.9 %
fiscal year 2025
Average annual growth
+1.1 %
Revenue growth over 5 years
Average annual growth
+2.0 %
Revenue growth over 10 years
Market cap
328 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202071.1 bn17.4 bn24.5 %n/a
202176.5 bn17.0 bn22.2 %+7.7 %
202280.2 bn15.1 bn18.9 %+4.8 %
202373.7 bn14.0 bn19.0 %-8.2 %
202476.0 bn10.1 bn13.3 %+3.2 %
202575.0 bn15.7 bn20.9 %-1.4 %

Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Roche Holding AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
3.96
safe zone (above 2.99)
Piotroski Score
6 / 9
4 to 6: average accounts
DCF Value
388.70 CHF
DCF close to share price · share price 390.30 CHF, gap -0.4 %
Net Debt / EBITDA
1.21 x
moderate debt
Fiscal year20212022202320242025
Cash and investments13.0 bn9.8 bn10.5 bn17.3 bn15.5 bn
Total Debt32.6 bn26.5 bn30.8 bn36.4 bn33.2 bn
Net Debt25.7 bn21.6 bn25.4 bn29.4 bn27.6 bn
Equity24.5 bn28.0 bn29.3 bn31.8 bn33.8 bn
Total assets92.3 bn88.2 bn90.5 bn102 bn101 bn
Operating cash flow20.6 bn17.9 bn16.1 bn20.1 bn17.8 bn
Investments (capex)4.5 bn4.6 bn3.7 bn3.5 bn5.8 bn
Free cash-flow16.0 bn13.3 bn11.4 bn15.1 bn14.1 bn
Share buybacks19.0 bn1.3 bn1.1 bn1.1 bn987 m
Dividends paid7.8 bn7.4 bn7.6 bn7.7 bn8.4 bn

Amounts in CHF, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)25.41 x
Price / book value9.66 x
Return on Equity (ROE)37.1 %
Return on Invested Capital (ROIC)20.8 %
Net margin20.2 %
Debt / equity0.97 x
Current ratio1.23 x
Interest coverage14.07 x
Free cash-flow yield5.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.

+

Valuation and competitors

Roche Holding AG compared with its sector on the same exchange and with its main competitors.

Company P/E
25.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Roche Holding AG338 bn26.520.9 %
Novartis AG NOVN.SW307 bn19.525.6 %
AbbVie Inc. ABBV521 bn28.96.9 %
Merck & Co., Inc. MRK369 bn46.628.1 %
Amgen Inc. AMGN252 bn20.821.0 %
Gilead Sciences, Inc. GILD212 bnn/a28.9 %
Novo Nordisk A/S NOVO-B.CO175 bn11.433.1 %
Pfizer Inc. PFE174 bn10.012.4 %

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Roche Holding AG publish: ratings, price targets and earnings forecasts.

Majority rating
hold
10 analysts

Breakdown of ratings

strong buy 0buy 4hold 5sell 1strong sell 0

Price targets: published for companies listed in the United States only.

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202663.4 bn16.4 bn20.46 (19.82 / 21.40)20.11
202766.6 bn17.8 bn22.15 (21.46 / 23.17)18.61
202869.6 bn19.1 bn23.81 (23.06 / 24.91)17.31

Amounts in CHF, the reporting currency.

Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Roche Holding AG: dividend history, last distributions, stock splits and earnings releases.

Frequency
annual
Last dividend
10.80 CHF
ex-dividend on 12/03/2026
Last 12 months
10.80 CHF
number of payments: 1
Yield
3.2 %
on the last known price
Years of increases
20
consecutive
Years of payments
31
uninterrupted
02.705.408.1010.802007 : 3.40 CHF2008 : 4.60 CHF20082009 : 5.00 CHF2010 : 6.00 CHF20102011 : 6.60 CHF2012 : 6.80 CHF20122013 : 7.35 CHF2014 : 7.80 CHF20142015 : 8.00 CHF2016 : 8.10 CHF20162017 : 8.20 CHF2018 : 8.30 CHF20182019 : 8.70 CHF2020 : 9.00 CHF20202021 : 9.10 CHF2022 : 9.30 CHF20222023 : 9.50 CHF2024 : 9.60 CHF20242025 : 9.70 CHF2026 : 10.80 CHF2026

Annual dividend per share (CHF), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
12/03/202610.80 CHF16/03/2026
27/03/20259.70 CHF31/03/2025
14/03/20249.60 CHF18/03/2024
16/03/20239.50 CHF20/03/2023
17/03/20229.30 CHF21/03/2022
18/03/20219.10 CHF22/03/2021
19/03/20209.00 CHF23/03/2020
07/03/20198.70 CHF11/03/2019

Earnings releases

DatePublished EPSExpected EPSSurprise
23/07/20268.5210.20-16.5 %
29/01/20268.168.37-2.5 %
24/07/202511.1110.48+6.0 %
30/01/20258.648.47+2.0 %
25/07/202410.059.20+9.2 %
01/02/20248.698.70-0.1 %

Stock splits

DateOperation
04/05/2011split: 100 shares for 1
04/05/2001split: 100 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Roche Holding AG.

Free float
27.2 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
SIX Swiss Exchange
IPO: 03/08/1995
ISIN code
CH0012032113
Workforce
103,249
full-time employees
Chief executive
Thomas Schinecker
Next earnings
28/01/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Roche Holding AG

What is the Roche Holding AG share price?

Latest recorded price: 400.00 CHF on 06/11/2026, for a market cap of 328 bn USD.

What is the revenue of Roche Holding AG?

75.0 bn USD for fiscal year 2025, with net income of 15.7 bn USD (net margin 20.9 %).

Does Roche Holding AG pay a dividend?

Yes. Latest dividend: 10.80 CHF per share, ex-dividend on 12/03/2026. Over 12 months: 10.80 CHF. Yield on the latest known price: 3.2 %.

When does Roche Holding AG report its next earnings?

The next release is expected on 28/01/2027. EPS expected by analysts: 9.62.

What do analysts say about Roche Holding AG?

Out of 10 analysts: 4 buy or strong buy, 5 hold, 1 sell or strong sell.

What is the P/E ratio of Roche Holding AG?

Trailing 12-month P/E of 25.8.

Is Roche Holding AG stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH0012032113).

How many employees does Roche Holding AG have?

103,249 full-time employees according to the latest published profile.

Who runs Roche Holding AG?

Thomas Schinecker is the company's chief executive.

07

Similar stocks